12:00 AM
 | 
Jan 14, 2013
 |  BC Week In Review  |  Company News  |  Deals

Gilead, MacroGenics deal

MacroGenics and Gilead partnered to develop and commercialize preclinical mAbs generated with MacroGenics' Dual-Affinity Re-Targeting (DART) technology against up to four targets. Gilead said the undisclosed targets are in cancer and "other...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >